From Streak to Summit: Integrated Proteins Ltd Hits All-Time High at Rs 83.44

Session Recap and Price Momentum

The stock opened at its peak price of Rs 83.44 and maintained this level throughout the trading session, reflecting strong investor conviction. Despite underperforming its sector, which gained 4.07% on the day, Integrated Proteins Ltd still outpaced the Sensex’s 1.06% gain with a 1.91% rise. This persistent upward trajectory over nearly three weeks has propelled the stock well beyond its previous 52-week high of Rs 57.75, a leap of 44.48% above that benchmark. The stock’s trading above all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—further underscores the bullish technical environment. Integrated Proteins Ltd’s delivery volumes have also surged, with a 63.52% increase over the past month and a notable 53.46% jump in daily delivery compared to the 5-day average, signalling strong hands holding the stock. Could this sustained momentum be signalling a durable uptrend or is a correction imminent?

Technical Indicators Paint a Bullish Picture

Technically, the stock’s trend shifted decisively to bullish on 27 Mar 2026 at Rs 71.33, and since then, momentum has accelerated. Weekly and monthly MACD indicators remain bullish, complemented by Bollinger Bands confirming upward price pressure. The Dow Theory also supports the current uptrend, while the KST indicator shows a mildly bearish signal on the monthly scale, suggesting some caution in longer-term momentum. The RSI, however, is bearish on the weekly timeframe, indicating the stock may be overbought in the short term. Immediate support is anchored at the 52-week low of Rs 20.71, a distant cushion given the current price, while resistance levels at the 20-day and 100-day moving averages have been decisively breached. How sustainable is this technical alignment given the mixed signals from momentum oscillators?

Valuation Multiples Suggest Elevated Premium

Despite the strong price performance, valuation metrics reveal a stretched premium. The trailing twelve months (TTM) price-to-earnings (P/E) ratio stands at an eye-catching 464x, far exceeding typical industry norms. Price-to-book value (P/BV) is 7.53x, while enterprise value to EBITDA and EBIT both hover at 153.23x, signalling a significant premium for earnings and cash flow. The EV/Sales multiple of 5.96x also suggests investors are pricing in substantial growth expectations. Dividend metrics are absent, with no dividend payout or yield reported, which may weigh on income-focused investors. This divergence between soaring price and lofty multiples raises questions about whether the current valuation is justified by fundamentals or if caution is warranted. At a P/E of 464x, is Integrated Proteins Ltd still worth holding — or is it time to reassess?

Financial Trend and Quality Metrics

On the financial front, Integrated Proteins Ltd shows a flat short-term trend as of December 2025, with quarterly earnings per share (EPS) at a low of ₹-0.06, indicating recent profitability pressures. However, the company boasts a robust 5-year sales growth of 92.87%, reflecting strong top-line expansion. EBIT growth over five years is more modest at 7.26%, and average EBIT to interest coverage is negative at -0.05x, signalling some strain in operational profitability relative to interest obligations. The balance sheet appears solid with negligible debt (debt to EBITDA at 0.46) and zero net debt to equity, alongside no promoter share pledging. Average return on capital employed (ROCE) and return on equity (ROE) are weak at -5.14% and 1.51% respectively, suggesting limited capital efficiency despite sales growth. What does the disconnect between strong sales growth and weak profitability imply for the company’s long-term financial health?

Key Data at a Glance

Sector and Market Context

Within the edible oil sector, Integrated Proteins Ltd’s performance stands out dramatically. While the solvent extraction segment gained 4.07% on the day, the stock’s 1.91% rise was modest in comparison but still outpaced the broader Sensex’s 1.06% advance. Over longer horizons, the stock’s returns dwarf market benchmarks: a 3-month gain of 156.42% versus a Sensex decline of 7.34%, and a 3-year return of 581.14% compared to Sensex’s 29.40%. The 10-year performance is even more striking at 3799.07%, underscoring a remarkable growth trajectory. However, the stock’s micro-cap status and below-average quality rating suggest investors should weigh the risks alongside the rewards. Does the stock’s outperformance relative to sector and market indices justify its stretched valuation?

Balancing the Bull and Bear Cases

The rally in Integrated Proteins Ltd is supported by a strong technical setup and an impressive run of consecutive gains, reflecting robust market enthusiasm. Yet, the valuation multiples are stretched to levels that typically warrant caution, especially given the company’s weak profitability metrics and flat recent financial trend. The absence of dividend payouts and the below-average quality rating further complicate the investment narrative. While the stock’s long-term sales growth is commendable, the low returns on capital and negative EBIT to interest coverage ratio highlight challenges in translating revenue into sustainable profits. Should you buy, sell, or hold? With momentum and valuations pulling in opposite directions, no single data point tells the full story — see the complete multi-factor analysis of Integrated Proteins Ltd to find out.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today